A detailed history of Lazard Asset Management LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 95,999 shares of ALKS stock, worth $2.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,999
Previous 83,711 14.68%
Holding current value
$2.95 Million
Previous $2.02 Million 33.22%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.01 - $28.55 $282,746 - $350,822
12,288 Added 14.68%
95,999 $2.69 Million
Q2 2024

Aug 14, 2024

BUY
$23.21 - $27.24 $153,394 - $180,029
6,609 Added 8.57%
83,711 $2.02 Million
Q1 2024

May 14, 2024

BUY
$26.4 - $32.56 $1.77 Million - $2.18 Million
66,890 Added 655.01%
77,102 $2.09 Million
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $53,844 - $66,078
2,304 Added 29.14%
10,212 $283,000
Q3 2023

Nov 14, 2023

BUY
$27.17 - $31.97 $214,860 - $252,818
7,908 New
7,908 $221,000
Q2 2022

Aug 09, 2022

SELL
$26.4 - $30.54 $72,283 - $83,618
-2,738 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$23.07 - $27.99 $63,165 - $76,636
2,738 New
2,738 $72,000
Q4 2021

Feb 09, 2022

SELL
$21.47 - $32.08 $52,236 - $78,050
-2,433 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$23.37 - $32.13 $56,859 - $78,172
2,433 New
2,433 $75,000
Q1 2021

May 14, 2021

SELL
$18.21 - $23.2 $50,077 - $63,800
-2,750 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$15.39 - $22.1 $42,322 - $60,775
2,750 New
2,750 $54,000
Q3 2020

Nov 13, 2020

SELL
$16.16 - $20.66 $64,025 - $81,854
-3,962 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$13.31 - $19.41 $34,246 - $49,941
-2,573 Reduced 39.37%
3,962 $76,000
Q1 2020

May 14, 2020

BUY
$13.06 - $21.24 $85,347 - $138,803
6,535 New
6,535 $94,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.05B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.